SUPRIYA LIFESCIENCE LTD.
Creating true values that bind global health

Date: December 9, 2024

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA

Dear Sir/Madam,

Subject: Press Release- Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval & Atorvastatin patent filing

Pursuant to the relevant provisions of the SEBI Listing Regulations, we are enclosing herewith Press Release "Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval & Atorvastatin patent filing".

Request you to kindly take the same on record.

Thanking you,

For Supriya Lifescience Limited

SHWETA SHIVDHARI SINGH

Digitally signed by SHWETA SHIVDHARI SINGH
DN: c=IN, o=PERSONAL, pseudonym=5ed61118f95249639l3aab8b2dd2f858, 2.5.4.20=7ecd6cc212b10d907bb2883c588d6eb1d1f28d80e13dba2ebd6975df438869e5, postalCode=400097, st=Maharashtra, serialNumber=b696ab674736edaacabe9d4e9a63ae406ea0e6dd83072b0cf6fa56593bffa9dd, cn=SHWETA SHIVDHARI SINGH
Date: 2024.12.09 14:38:54 +05'30'

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: **supriya@supriyalifescience .com** Website: **www.supriyalifescience.com**

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

SUPRIYA LIFESCIENCE LTD.

Press Release for immediate distribution.

Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval & Atorvastatin patent filing

- Supriya Lifescience becomes the first Indian company to receive nod for Esketamine Hydrochloride from Brazil's health authority ANVISA.
- Supriya Lifescience have developed groundbreaking technique for low-cost manufacturing of Atorvastatin, which is worldwide used for a key treatment for controlling cholesterol and preventing cardiovascular disease.

Mumbai, December 9, 2024: Supriya Lifescience Ltd., a global pharmaceutical industry leader, achieved two significant milestones, strengthening its position in international markets. The company has acquired approval from Brazil's health authority, ANVISA (Agência Nacional de Vigilância Sanitária), for Esketamine Hydrochloride, which is a major step in growing its product range in Brazil and the rest of LATAM. Supriya Lifescience is the first firm in Brazil to have received regulatory permission for this highly specialised pharmaceutical.

Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing.

Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility.

Dr. Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience Ltd. stated, *"Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil."*

With CADIFA approval in place, Supriya Lifescience is now ready to tap into the fast-growing LATAM market. The company's continued focus on innovation, regulatory compliance, and its mission to make high-quality healthcare accessible globally positions it as a key player in the international pharmaceutical landscape.

……

About Supriya Lifescience Ltd.:

Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company's primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.

For Media Queries:

Abhishek Chawande
Dentsu Creative PR
M: 9664516774
e-mail: abhishek.chawande@dentsu.com